USD 0.16
(0.65%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -38.64 Million USD | 60.1% |
2022 | -96.83 Million USD | 25.14% |
2021 | -129.36 Million USD | -334.78% |
2020 | -29.75 Million USD | -757.74% |
2019 | -3.46 Million USD | -850.87% |
2018 | 462 Thousand USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | 255.33 Million USD | 924.25% |
2024 Q1 | -30.97 Million USD | 19.83% |
2023 Q4 | -38.64 Million USD | -93.88% |
2023 FY | -38.64 Million USD | 60.1% |
2023 Q1 | -26.1 Million USD | 73.05% |
2023 Q2 | -46.38 Million USD | -77.74% |
2023 Q3 | -19.93 Million USD | 57.04% |
2022 Q4 | -96.83 Million USD | 27.85% |
2022 Q3 | -134.21 Million USD | -37.48% |
2022 Q2 | -97.62 Million USD | 5.6% |
2022 Q1 | -103.42 Million USD | 20.06% |
2022 FY | -96.83 Million USD | 25.14% |
2021 Q3 | -344.63 Million USD | 23.34% |
2021 FY | -129.36 Million USD | -334.78% |
2021 Q4 | -129.36 Million USD | 62.46% |
2021 Q2 | -449.53 Million USD | 29.64% |
2021 Q1 | -638.9 Million USD | -2047.22% |
2020 FY | -29.75 Million USD | -757.74% |
2020 Q2 | -9.34 Million USD | -107.86% |
2020 Q4 | -29.75 Million USD | -257.55% |
2020 Q3 | -8.32 Million USD | 10.93% |
2020 Q1 | 118.87 Million USD | 3526.64% |
2019 FY | -3.46 Million USD | -850.87% |
2019 Q4 | -3.46 Million USD | 0.0% |
2019 Q1 | 138 Thousand USD | 0.0% |
2018 FY | 462 Thousand USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
ADC Therapeutics SA | -154.22 Million USD | 74.944% |
Alto Neuroscience, Inc. | 68.91 Million USD | 156.072% |
Annovis Bio, Inc. | -5.75 Million USD | -571.484% |
Biohaven Pharmaceutical Holding Company Ltd. | -218.84 Million USD | 82.343% |
Ginkgo Bioworks Holdings, Inc. | -707.09 Million USD | 94.535% |
Nuvation Bio Inc. | -38.64 Million USD | -0.0% |
Arcus Biosciences, Inc. | -116 Million USD | 66.688% |
Theriva Biologics, Inc. | -21.02 Million USD | -83.808% |
Zymeworks Inc. | -130.83 Million USD | 70.465% |